{"id":"https://openalex.org/W2763899732","doi":"https://doi.org/10.1093/annonc/mdx365.005","title":"Initial results of a phase 1 dose expansion cohort of M6620 (formerly VX-970), an ATR inhibitor, in combination with cisplatin in patients with advanced triple-negative breast cancer NCT02157792)","display_name":"Initial results of a phase 1 dose expansion cohort of M6620 (formerly VX-970), an ATR inhibitor, in combination with cisplatin in patients with advanced triple-negative breast cancer NCT02157792)","publication_year":2017,"publication_date":"2017-09-01","ids":{"openalex":"https://openalex.org/W2763899732","doi":"https://doi.org/10.1093/annonc/mdx365.005","mag":"2763899732"},"language":"en","primary_location":{"id":"doi:10.1093/annonc/mdx365.005","doi":"https://doi.org/10.1093/annonc/mdx365.005","is_oa":true,"landing_page_url":"https://doi.org/10.1093/annonc/mdx365.005","pdf_url":"https://academic.oup.com/annonc/article-pdf/28/suppl_5/mdx365.005/19938723/mdx365.005.pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://academic.oup.com/annonc/article-pdf/28/suppl_5/mdx365.005/19938723/mdx365.005.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052487618","display_name":"Melinda L. Telli","orcid":"https://orcid.org/0000-0001-7993-1235","observed_orcids":["https://orcid.org/0000-0001-7993-1235"]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M.L. Telli","raw_affiliation_strings":["Oncology, Stanford University School of Medicine, Stanford, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Stanford University School of Medicine, Stanford, CA, USA","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085866945","display_name":"Simon Lord","orcid":"https://orcid.org/0000-0001-7946-5609","observed_orcids":["https://orcid.org/0000-0001-7946-5609"]},"institutions":[{"id":"https://openalex.org/I2801179840","display_name":"Churchill Hospital","ror":"https://ror.org/009vheq40","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2801179840","https://openalex.org/I4210147381"]},{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S. Lord","raw_affiliation_strings":["Department of Oncology, Churchill Hospital, University of Oxford, Oxford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Churchill Hospital, University of Oxford, Oxford, UK","institution_ids":["https://openalex.org/I2801179840","https://openalex.org/I40120149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000462280","display_name":"Emma Jane Dean","orcid":"https://orcid.org/0000-0001-9956-257X","observed_orcids":["https://orcid.org/0000-0001-9956-257X"]},"institutions":[{"id":"https://openalex.org/I4210131968","display_name":"The Christie Hospital","ror":"https://ror.org/03nd63441","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210131968","https://openalex.org/I4210133995"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"E. Dean","raw_affiliation_strings":["Oncology, The Christie NHS Foundation Trust, Manchester, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, The Christie NHS Foundation Trust, Manchester, UK","institution_ids":["https://openalex.org/I4210131968","https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051977006","display_name":"V. G. Abramson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"V. Abramson","raw_affiliation_strings":["Division of Hematology, Vanderbilt University Medical Center, Nashville, TN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Vanderbilt University Medical Center, Nashville, TN, USA","institution_ids":["https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012989377","display_name":"Hendrik\u2010Tobias Arkenau","orcid":"https://orcid.org/0000-0002-2015-1549","observed_orcids":["https://orcid.org/0000-0002-2015-1549","https://orcid.org/0000-0003-0372-0540"]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"H-T. Arkenau","raw_affiliation_strings":["Oncology, Sarah Cannon Research Institute SCRI UK, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Sarah Cannon Research Institute SCRI UK, London, UK","institution_ids":["https://openalex.org/I172427033"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108558388","display_name":"Carlos Roberto Becerra","orcid":"https://orcid.org/0009-0006-7735-8010","observed_orcids":["https://orcid.org/0009-0006-7735-8010"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Becerra","raw_affiliation_strings":["Baylor Charles A. Sammons Cancer Center, Texas Oncology, Dallas, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Baylor Charles A. Sammons Cancer Center, Texas Oncology, Dallas, TX, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069056507","display_name":"Sara M. Tolaney","orcid":"https://orcid.org/0000-0002-5940-8671","observed_orcids":["https://orcid.org/0000-0002-5940-8671"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S.M. Tolaney","raw_affiliation_strings":["Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":null,"display_name":"R. Tang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Tang","raw_affiliation_strings":["Oncology, Vertex Pharmaceuticals Incorporated, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Vertex Pharmaceuticals Incorporated, Boston, MA, USA","institution_ids":["https://openalex.org/I61970326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110502323","display_name":"Marina S. Penney","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M.S. Penney","raw_affiliation_strings":["Oncology, Vertex Pharmaceuticals Incorporated, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Vertex Pharmaceuticals Incorporated, Boston, MA, USA","institution_ids":["https://openalex.org/I61970326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085072340","display_name":"John Robert Pollard","orcid":"https://orcid.org/0009-0001-7995-9606","observed_orcids":["https://orcid.org/0009-0001-7995-9606"]},"institutions":[{"id":"https://openalex.org/I4210127480","display_name":"Vertex Pharmaceuticals (United Kingdom)","ror":"https://ror.org/03fs5jd74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210127480","https://openalex.org/I61970326"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. Pollard","raw_affiliation_strings":["Oncology, Vertex Pharmaceuticals Limited, Oxford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Vertex Pharmaceuticals Limited, Oxford, UK","institution_ids":["https://openalex.org/I4210127480"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076294850","display_name":"G. Conboy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G. Conboy","raw_affiliation_strings":["Oncology, Vertex Pharmaceuticals Incorporated, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Vertex Pharmaceuticals Incorporated, Boston, MA, USA","institution_ids":["https://openalex.org/I61970326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111813748","display_name":"Scott Z. Fields","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S.Z. Fields","raw_affiliation_strings":["Oncology, Vertex Pharmaceuticals Incorporated, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Vertex Pharmaceuticals Incorporated, Boston, MA, USA","institution_ids":["https://openalex.org/I61970326"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5045419282","display_name":"Geoffrey Ira Shapiro","orcid":"https://orcid.org/0000-0002-3331-4095","observed_orcids":["https://orcid.org/0000-0002-3331-4095"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G. Shapiro","raw_affiliation_strings":["Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":11,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5080,"currency":"USD","value_usd":5080},"apc_paid":null,"fwci":0.1213,"has_fulltext":true,"cited_by_count":3,"citation_normalized_percentile":{"value":0.53495874,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"28","issue":null,"first_page":"v76","last_page":"v76"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9014000296592712,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9014000296592712,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.054099999368190765,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.01720000058412552,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vx-970","display_name":"VX-970","score":0.9959999918937683},{"id":"https://openalex.org/keywords/atr-inhibitors","display_name":"ATR inhibitors","score":0.9810000061988831},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.9829999804496765},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.9829999804496765},{"id":"https://openalex.org/keywords/dna-repair","display_name":"DNA repair","score":0.5879999995231628},{"id":"https://openalex.org/keywords/homologous-recombination","display_name":"homologous recombination","score":0.9480000138282776},{"id":"https://openalex.org/keywords/replication-stress","display_name":"replication stress","score":0.8040000200271606},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6570000052452087},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.7540000081062317}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8682118654251099},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.698430061340332},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.6611440777778625},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.6492322683334351},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.594327986240387},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.5324820876121521},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.522128164768219},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5068491101264954},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.424323707818985},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.42367038130760193},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.4196126461029053},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.41700485348701477},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.37680763006210327}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1093/annonc/mdx365.005","doi":"https://doi.org/10.1093/annonc/mdx365.005","is_oa":true,"landing_page_url":"https://doi.org/10.1093/annonc/mdx365.005","pdf_url":"https://academic.oup.com/annonc/article-pdf/28/suppl_5/mdx365.005/19938723/mdx365.005.pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1093/annonc/mdx365.005","doi":"https://doi.org/10.1093/annonc/mdx365.005","is_oa":true,"landing_page_url":"https://doi.org/10.1093/annonc/mdx365.005","pdf_url":"https://academic.oup.com/annonc/article-pdf/28/suppl_5/mdx365.005/19938723/mdx365.005.pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320317987","display_name":"Syndax Pharmaceuticals","ror":"https://ror.org/02w9kv048"},{"id":"https://openalex.org/F4320328455","display_name":"Ipsen","ror":"https://ror.org/00d801g55"},{"id":"https://openalex.org/F4320338262","display_name":"Daiichi Sankyo Europe","ror":"https://ror.org/01qhj1g70"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2763899732.pdf","grobid_xml":"https://content.openalex.org/works/W2763899732.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2789244646","https://openalex.org/W2501241795","https://openalex.org/W2582783922","https://openalex.org/W2346506773","https://openalex.org/W2680204723","https://openalex.org/W2898339762","https://openalex.org/W2889136929","https://openalex.org/W2889859034","https://openalex.org/W2099957817","https://openalex.org/W3036123907"],"abstract_inverted_index":null,"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2017-10-20T00:00:00"}